Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Boehringer announces collaboration with PetMedix
PetMedix's Ky9 platform can rapidly and efficiently generate fully canine therapeutic antibodies.
Partnership will see the development of companion animal antibody therapeutics.

Boehringer Ingelheim has announced a multi-year partnership with PetMedix - a Cambridge-based biopharmaceutical firm - to develop novel and transformative companion animal antibody therapeutics.

The collaboration will see PetMedix undertake discovery activities against a number of key targets and Boehringer Ingelheim will work to develop and bring these therapies to market. The terms of the partnership have not been disclosed. 

PetMedix’s breakthrough approach to therapeutic antibodies has resulted in a number of successful, novel therapies for humans. It is also the only company in the world that has been able to bring this approach to veterinary medicine.

Through its its Ky9™ platform, PetMedix can rapidly and efficiently generate fully canine therapeutic antibodies. This approach saves time and money in drug development, and reduces the risk of certain key adverse events relative to other antibody technologies.

Dr Tom Weaver, CEO of PetMedix, said: “We are excited to be working with Boehringer Ingelheim on this project as we feel we bring complementary experience and expertise to this partnership. PetMedix has developed the leading pet antibody discovery engine, and it will be through Boehringer Ingelheim’s global scale and industry leadership that these novel therapies will best be able to succeed and ultimately benefit the animals.”

James Allan, global head of transaction, business development & licensing, Boehringer Ingelheim Animal Health, added: “Boehringer Ingelheim is pleased to be working with PetMedix on this cutting edge technology as a means to bring innovative new therapies to improve the health of animals globally. PetMedix has a unique expertise and its focus on innovation aligns well with our own”.

Become a member or log in to add this story to your CPD history

RCVS announces 1CPD app update

News Story 1
 The RCVS has announced a new version of its 1CPD mobile app, with enhanced features for veterinary surgeons and veterinary nurses to record their continuing professional development.

The mobile app includes a new 'what would you like to do?' shortcut for frequent tasks, a notification badge, and the ability to scan a QR code from the home screen to easily record an activity.

Users will be prompted to update the app from the App Store or Google Play the next time they log in. For more information, visit RCVS.org.uk 

Click here for more...
News Shorts
Nominations open for RCVS and VN Council elections

The nomination period for the 2026 RCVS Council and VN Council elections is now open, with three veterinary surgeon seats and two veterinary nurse seats available.

Prospective candidates can download an information pack and nomination form from the RCVS website. Individuals can nominate themselves for the elections, with the results to be announced in the spring.

Clare Paget, the recently appointed RCVS Registrar and elections returning officer, said: "If you want to play your part in influencing and moulding how the professions are regulated, and making key decisions on matters of great importance to your peers, the public and animal health and welfare, please consider standing for RCVS Council or VN Council next year."

Nominations close at 5pm on Saturday, 31 January 2026.